What To Know About Jiyoutai—China's First Potential O

The new biosimilar drug could pose the first major challenge to Ozempic in China, where Novo Nordisk’s patent is set to expire in 2026.

Related Keywords

Hong Kong , Jiuyuan , Hunan , China , Chinese , Mette Kruse Danielsen , Eli Lilly , China Intellectual Property Office , Reuters , Drug Administration , Novo Nordisk , Jiuyuan Gene Engineering , Jiuyuan Gene , Wall Street , Intellectual Property Office , Chinese Based Innovent , Ozempic ,